Numerous epidemiologic and serologic studies of SARS-CoV
(9-11,13) have suggested that the SARS-CoV
N protein could serve as a diagnostic marker because of its early appearance (11), the long persistence of serum-specific IgG (14), and concordance in sensitive and specific immunoassays (9-11,14) during SARS infection.
The serum samples were tested for IgG antibodies reactive with the S1 antigens of MERS-CoV and severe acute respiratory syndrome coronavirus (SARS-CoV
), and titers were calculated as described previously (4,5).
Development and evaluation of an efficient 3'-noncoding region based SARS coronavirus (SARS-CoV
) RT-PCR assay for detection of SARS-CoV
The SARS coronavirus, sometimes shortened to SARS-CoV
, is the virus that causes severe acute respiratory syndrome (SARS).
Researchers from University of Iowa have found that mice treated with the protein, Griffithsin (GRFT), had a 100 percent survival rate after exposure to the SARS coronavirus (SARS-CoV
), as compared to a 30 percent survival for untreated mice.
T-cell responses are critical for protection from subsequent challenge in animals experimentally infected with SARS-CoV
The vaccine contains a fragment of SARS-CoV
DNA that is too small to reproduce but large enough to produce a protective immune response.
A vaccine developed at the Vaccine Research Center of the National Institute of Allergy and Infectious Diseases appears to prevent replication of the severe acute respiratory syndrome coronavirus (SARS-CoV
) in mice.
Exploring the pathogenesis of severe acute respiratory syndrome (SARS): the tissue distribution of the coronavirus (SARS-CoV
) and its putative receptor, angiotensin-converting enzyme 2 (ACE2).
associated pediatric mortality, and in 2003 for SARS-CoV
Peripheral blood mononuclear cells (PBMCs) obtained on day 24 of illness showed a strong specific T-cell response against MERS-CoV spike protein but not against severe acute respiratory syndrome coronavirus (SARS-CoV
) spike protein (online Technical Appendix Figure 3, panel C).